Published in J Clin Oncol on June 01, 2003
A proposal for the timing of management of patients with melanoma presenting during pregnancy. J Surg Oncol (2012) 1.40
Immunologically silent cancer clone transmission from mother to offspring. Proc Natl Acad Sci U S A (2009) 1.07
Cancer treatment in pregnant women. Contemp Oncol (Pozn) (2014) 0.80
Metastatic Malignant Melanoma during Pregnancy: Case report and a Review of the literature. Sultan Qaboos Univ Med J (2009) 0.77
Challenges in managing breast cancer during pregnancy. J Thorac Dis (2013) 0.76
Foetal defence against cancer: a hypothesis. J Cell Mol Med (2013) 0.76
Melanoma in pregnancy: a case report and review of the literature. Postepy Dermatol Alergol (2015) 0.76
Investigation of normal organ development with fetal MRI. Eur Radiol (2007) 0.76
Aggressive Breast Cancer during Pregnancy with a Rare Form of Metastasis in the Maternal Placenta. Geburtshilfe Frauenheilkd (2014) 0.75
Tolerance to noninherited maternal antigens, reproductive microchimerism and regulatory T cell memory: 60 years after 'Evidence for actively acquired tolerance to Rh antigens'. Chimerism (2015) 0.75
Cancer in pregnancy: disentangling treatment modalities. ESMO Open (2016) 0.75
Breast cancer in pregnancy: a literature review. Facts Views Vis Obgyn (2009) 0.75
Atrial and placental melanoma metastasis: a case report and literature review. J Med Case Rep (2007) 0.75
Maternal to fetal transmission of cervical carcinoma. Pediatr Radiol (2014) 0.75
Metastatic melanoma positively influences pregnancy outcome in a mouse model: could a deadly tumor support embryo life? Clin Exp Metastasis (2007) 0.75
Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol (2007) 5.39
Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol (2010) 4.81
Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol (2006) 2.60
A giant verruciform xanthoma. J Cutan Pathol (2002) 2.59
High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res (2006) 2.40
Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma. J Clin Oncol (2007) 2.19
Correlation between prognostic factors and increasing age in melanoma. Ann Surg Oncol (2004) 2.18
Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet (2006) 2.17
Absence of senescence-associated beta-galactosidase activity in human melanocytic nevi in vivo. J Invest Dermatol (2007) 2.11
The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol (2002) 2.10
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest New Drugs (2010) 2.09
Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol (2012) 2.02
Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma. J Clin Oncol (2006) 1.85
The dysplastic nevus: from historical perspective to management in the modern era: part I. Historical, histologic, and clinical aspects. J Am Acad Dermatol (2012) 1.79
Reflectance spectrophotometer: the dermatologists' sphygmomanometer for skin phototyping? J Invest Dermatol (2008) 1.65
Frequency of nonsentinel lymph node metastasis in melanoma. Ann Surg Oncol (2002) 1.62
Case series of multiple recurrent reactive keratoacanthomas developing at surgical margins. Dermatol Surg (2009) 1.60
Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. Ann Surg Oncol (2012) 1.56
Complications associated with sentinel lymph node biopsy for melanoma. Ann Surg Oncol (2003) 1.52
Keratin K6c mutations cause focal palmoplantar keratoderma. J Invest Dermatol (2009) 1.51
Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine. Mol Pharmacol (2004) 1.50
Rapid induction of mitochondrial events and caspase-independent apoptosis in Survivin-targeted melanoma cells. Oncogene (2004) 1.49
Comparative analysis of total body and dermatoscopic photographic monitoring of nevi in similar patient populations at risk for cutaneous melanoma. Dermatol Surg (2010) 1.46
Single-nucleotide-specific siRNA targeting in a dominant-negative skin model. J Invest Dermatol (2007) 1.46
Clinical genetic testing for familial melanoma in Italy: a cooperative study. J Am Acad Dermatol (2009) 1.45
Longitudinal assessment of the nevus phenotype in a melanoma kindred. J Invest Dermatol (2004) 1.44
Mohs appropriate use criteria: retrospectively applied to nonmelanoma skin cancers at a single academic center. Dermatol Surg (2015) 1.43
A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg (2009) 1.39
Apoptosis regulators and responses in human melanocytic and keratinocytic cells. J Invest Dermatol (2003) 1.39
Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. J Clin Oncol (2011) 1.39
Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation. J Clin Oncol (2005) 1.35
The genetic basis of pachyonychia congenita. J Investig Dermatol Symp Proc (2005) 1.34
Interval sentinel lymph nodes in melanoma. Arch Surg (2002) 1.32
Gender-related differences in outcome for melanoma patients. Ann Surg (2006) 1.32
Survivin repression by p53, Rb and E2F2 in normal human melanocytes. Carcinogenesis (2007) 1.29
Strongly positive tissue transglutaminase antibodies are associated with Marsh 3 histopathology in adult and pediatric celiac disease. J Clin Gastroenterol (2008) 1.29
Keratinocyte apoptosis in epidermal development and disease. J Invest Dermatol (2006) 1.28
Phospholipid scramblase 3 controls mitochondrial structure, function, and apoptotic response. Mol Cancer Res (2003) 1.26
A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer (2010) 1.24
CDKN2A/p16 genetic test reporting improves early detection intentions and practices in high-risk melanoma families. Cancer Epidemiol Biomarkers Prev (2008) 1.22
Predictors of sun protection behaviors and severe sunburn in an international online study. Cancer Epidemiol Biomarkers Prev (2010) 1.21
Co-occurrence of celiac disease and other autoimmune diseases in celiacs and their first-degree relatives. J Autoimmun (2008) 1.20
Melanoma genetics: a review of genetic factors and clinical phenotypes in familial melanoma. Curr Opin Oncol (2006) 1.17
Lessons learned from the Sunbelt Melanoma Trial. J Surg Oncol (2004) 1.15
Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol (2002) 1.15
A review of the clinical phenotype of 254 patients with genetically confirmed pachyonychia congenita. J Am Acad Dermatol (2012) 1.15
Correlation of duodenal histology with tissue transglutaminase and endomysial antibody levels in pediatric celiac disease. Clin Gastroenterol Hepatol (2007) 1.13
UVB-induced apoptosis drives clonal expansion during skin tumor development. Carcinogenesis (2004) 1.13
Genotype-phenotype correlations among pachyonychia congenita patients with K16 mutations. J Invest Dermatol (2010) 1.13
Treatment of pachyonychia congenita. J Investig Dermatol Symp Proc (2005) 1.13
Dermatofibrosarcoma protuberans. J Natl Compr Canc Netw (2012) 1.11
Melanocyte expression of survivin promotes development and metastasis of UV-induced melanoma in HGF-transgenic mice. Cancer Res (2007) 1.10
Prevalence of celiac disease among relatives of sib pairs with celiac disease in U.S. families. Am J Gastroenterol (2003) 1.09
Treatment of lentigo maligna with imiquimod before staged excision. Dermatol Surg (2007) 1.09
Phase II study of carboplatin in children with progressive low-grade gliomas. J Clin Oncol (2002) 1.07
Survivin enhances motility of melanoma cells by supporting Akt activation and {alpha}5 integrin upregulation. Cancer Res (2010) 1.06
Population-based prevalence of CDKN2A mutations in Utah melanoma families. J Invest Dermatol (2006) 1.05
Metastatic melanoma - a review of current and future treatment options. Acta Derm Venereol (2015) 1.05
Preradiation chemotherapy in primary high-risk brainstem tumors: phase II study CCG-9941 of the Children's Cancer Group. J Clin Oncol (2002) 1.05
Population-based analysis of prognostic factors and survival in familial melanoma. J Clin Oncol (2005) 1.04
Melanoma cells express elevated levels of phosphorylated histone H2AX foci. J Invest Dermatol (2005) 1.04
Role of the apoptotic and mitotic regulator survivin in melanoma. Anticancer Res (2012) 1.03
Low rates of clinical recurrence after biopsy of benign to moderately dysplastic melanocytic nevi. J Am Acad Dermatol (2009) 1.03
Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis. Ann Surg Oncol (2009) 1.03
IgA anti-epidermal transglutaminase antibodies in dermatitis herpetiformis and pediatric celiac disease. J Invest Dermatol (2009) 1.03
Fitness of children with standard-risk acute lymphoblastic leukemia during maintenance therapy: response to a home-based exercise and nutrition program. J Pediatr Hematol Oncol (2009) 1.03
Patterns of early recurrence after sentinel lymph node biopsy for melanoma. Am J Surg (2002) 1.02
A spectrum of mutations in keratins K6a, K16 and K17 causing pachyonychia congenita. J Dermatol Sci (2007) 1.00
Clinical germline genetic testing for melanoma. Lancet Oncol (2004) 1.00
Survivin expression in mouse skin prevents papilloma regression and promotes chemical-induced tumor progression. Cancer Res (2003) 1.00
Use of self-delivery siRNAs to inhibit gene expression in an organotypic pachyonychia congenita model. J Invest Dermatol (2011) 1.00
Melanoma genetic counseling and test reporting improve screening adherence among unaffected carriers 2 years later. Cancer Epidemiol Biomarkers Prev (2013) 0.99
A large mutational study in pachyonychia congenita. J Invest Dermatol (2011) 0.99
N-acetylcysteine protects melanocytes against oxidative stress/damage and delays onset of ultraviolet-induced melanoma in mice. Clin Cancer Res (2007) 0.98
Genetic testing for hereditary melanoma and pancreatic cancer: a longitudinal study of psychological outcome. Psychooncology (2011) 0.98
Frequency of sentinel lymph node metastases in patients with favorable breast cancer histologic subtypes. Am J Surg (2002) 0.98
Phosphorylation of mitochondrial phospholipid scramblase 3 by protein kinase C-delta induces its activation and facilitates mitochondrial targeting of tBid. J Cell Biochem (2007) 0.97
The depletion of DNA methyltransferase-1 and the epigenetic effects of 5-aza-2'deoxycytidine (decitabine) are differentially regulated by cell cycle progression. Epigenetics (2011) 0.97
Proliferation, apoptosis, and survivin expression in keratinocytic neoplasms and hyperplasias. Am J Dermatopathol (2004) 0.97
Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. J Am Acad Dermatol (2002) 0.97
Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma. Ann Surg (2010) 0.96
The dysplastic nevus: from historical perspective to management in the modern era: part II. Molecular aspects and clinical management. J Am Acad Dermatol (2012) 0.96
Use of oral N-acetylcysteine for protection of melanocytic nevi against UV-induced oxidative stress: towards a novel paradigm for melanoma chemoprevention. Clin Cancer Res (2009) 0.96
Sentinel lymph node biopsy for head and neck melanomas. Ann Surg Oncol (2003) 0.96
Role of phospholipid scramblase 3 in the regulation of tumor necrosis factor-alpha-induced apoptosis. Biochemistry (2008) 0.96
Molecular classification of melanoma using real-time quantitative reverse transcriptase-polymerase chain reaction. Cancer (2005) 0.96